Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
Fätkenheuer G, Jessen H, Stoehr A, Jung N, Jessen AB, Kümmerle T, Berger M, Bogner JR, Spinner CD, Stephan C, Degen O, Vogelmann R, Spornraft-Ragaller P, Schnaitmann E, Jensen B, Ulmer A, Kittner JM, Härter G, Malfertheiner P, Rockstroh J, Knecht G, Scholten S, Harrer T, Kern WV, Salzberger B, Schürmann D, Ranneberg B. Fätkenheuer G, et al. Among authors: harter g. HIV Med. 2016 Jun;17(6):453-9. doi: 10.1111/hiv.12363. Epub 2016 May 11. HIV Med. 2016. PMID: 27166295 Free article. Clinical Trial.
Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner JR, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stöhr A, Degen O, Freiwald E, Hüfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse AW, van Lunzen J, Schmiedel S; IDEAL study group. Schäfer G, et al. Among authors: harter g. AIDS Res Ther. 2019 Nov 15;16(1):34. doi: 10.1186/s12981-019-0250-2. AIDS Res Ther. 2019. PMID: 31729999 Free PMC article. Clinical Trial.
Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.
Hoffmann C, Casado JL, Härter G, Vizcarra P, Moreno A, Cattaneo D, Meraviglia P, Spinner CD, Schabaz F, Grunwald S, Gervasoni C. Hoffmann C, et al. Among authors: harter g. HIV Med. 2021 May;22(5):372-378. doi: 10.1111/hiv.13037. Epub 2020 Dec 27. HIV Med. 2021. PMID: 33368966 Free article.
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany.
Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, Krauss AS, Kolarikal H, Scholten S, Schuler C, Bickel M, Roll C, Kreckel P, Köppe S, Straub M, Klausen G, Lenz J, Esser S, Jensen B, Rausch M, Unger S, Pauli R, Härter G, Müller M, Masuhr A, Schäfer G, Seybold U, Schellberg S, Schneider J, Monin MB, Wolf E, Spinner CD, Boesecke C. Hoffmann C, et al. Among authors: harter g. HIV Med. 2023 Apr;24(4):389-397. doi: 10.1111/hiv.13378. Epub 2022 Sep 4. HIV Med. 2023. PMID: 36059149
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M, Seybold U, Roider J, Härter G, Bogner JR. Gomez M, et al. Among authors: harter g. Infection. 2019 Feb;47(1):95-102. doi: 10.1007/s15010-018-1227-0. Epub 2018 Sep 29. Infection. 2019. PMID: 30269210 Free PMC article.
Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M, Seybold U, Roider J, Härter G, Bogner JR. Gomez M, et al. Among authors: harter g. Infection. 2019 Feb;47(1):103-104. doi: 10.1007/s15010-018-1251-0. Infection. 2019. PMID: 30456685 Free PMC article.
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6. Clin Gastroenterol Hepatol. 2021. PMID: 31706062 Free article.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).
Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft. Thoden J, et al. Among authors: harter g. Infection. 2013 Sep;41 Suppl 2(Suppl 2):S91-115. doi: 10.1007/s15010-013-0504-1. Epub 2013 Sep 14. Infection. 2013. PMID: 24037688 Free PMC article.
58 results